Seres Therapeutics (MCRB) Non-Current Deferred Tax Liability (2022 - 2024)
Seres Therapeutics (MCRB) posted Non-Current Deferred Tax Liability of $50.6 million for Q4 2024, down 50.7% sequentially from $102.6 million in Q4 2023, and down 50.7% YoY from $102.6 million in Q1 2024.
Seres Therapeutics (MCRB) Non-Current Deferred Tax Liability (2022 - 2024) Analysis & Trends
Seres Therapeutics has reported Non-Current Deferred Tax Liability for 3 years, with the latest figure at $50.6 million in Q4 2024.
- Quarterly Non-Current Deferred Tax Liability fell 50.7% year-over-year to $50.6 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $50.6 million (down 50.7% YoY) and the FY2024 annual result came in at $50.6 million, down 50.7% from the prior year.
- Non-Current Deferred Tax Liability fell to $50.6 million in Q4 2024 per MCRB's latest filing, from $102.6 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $160.6 million in Q4 2022 and troughed at $50.6 million in Q4 2024.
- A 3-year average of $104.6 million and a median of $102.6 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
- The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability slumped 36.14% in 2023, then sank 50.7% in 2024.
- Over 3 years, Non-Current Deferred Tax Liability stood at $160.6 million in 2022, then plunged by 36.14% to $102.6 million in 2023, then sank by 50.7% to $50.6 million in 2024.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $50.6 million, $102.6 million, and $160.6 million for Q4 2024, Q4 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Seres Therapeutics | 43.87 Mn | 43.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 50.56 Mn |
| Dec 31, 2024 | 50.56 Mn |
| Dec 31, 2023 | 102.56 Mn |
| Dec 31, 2023 | 102.56 Mn |
| Dec 31, 2022 | 160.59 Mn |
| Dec 31, 2022 | 160.59 Mn |